Objective To observe the clinical effect of thymic peptide combined with chemotherapy in the treatment of lung cancer and its effect on the levels of ET-1 and T lymphocyte subtypes .Methods One 116 cases of patients with lung cancer were selected , which were treated in hospital from October 2012 to October 2015 , and they were divided into the obser-vation group (58 cases) and control group (58 cases).The patients of two groups were treated with Antiemetic , diuretic hy-dration and prevention of phlebitis before chemotherapy .The patients of control group with small cell lung cancer were treated with EP chemotherapy .The patients of control group with non-small cell lung cancer were treated with TP chemotherapy .On the basis of control group, the patients of observation group were treated with thymopentin ( 10 mg, intramuscular injection , 1 times /d, continuous application for 15d).A course of treatment were 15d, and with a total of four courses.Observe the clinic results, occurrence of adverse reactions , EORTC QLQ-C30 quality of life questionnaire score , changes of serum and EBC ET-1,serum ALB, CD4 +, CD8 +, CD4 +/CD8 +, NK of two groups.Results After chemotherapy, the patients of the observation group got a total efficiency of 63.8%, which was significantly better than the 56.9%of the control group (χ2 =4.772, P =0.029); In the terms of ET-1, the patients of two groups were all significantly decreased than before ( P <0.05), and the patients of the observation group got more significant decline ( t =18.193, t=15.405, P =0.000, P =0.000);In the terms of ALB, CD4 +, CD8 +, CD4 +/CD8 +, NK and QOL, the patients of two groups were all significantly improved than before ( P <0.05), and the patients of the observation group got more significant improvement ( t =5.031, t =5.676, t =2.532, t =4.901, t =7.577;P =0.000, P =0.000, P =0.006, P =0.000, P =0.000);the patients of the observation group got a incidence of gastrointestinal reactions of 15.5%, which was significantly less than the 39.6%of the control group (χ2 =8 6.458, P =0.004 ).Conclusion With treating patients with lung cancer , thymopentin combined with chemotherapy is effective to reduce the level of ET-1, inhibit tumor metastasis, and improve the immune function and the quality of life of patients .%目的：观察胸腺五肽联合化疗治疗肺癌的临床效果及对ET-1、T淋巴细胞亚群水平的影响。方法选取2012年10月—2015年10月内蒙古自治区人民医院肿瘤内科收治的肺癌患者116例作为研究对象，按随机数字表法分为观察组58例和对照组58例。2组患者在化疗前给予止吐、预防静脉炎及水化利尿等常规治疗，小细胞肺癌采用EP化疗方案，非小细胞肺癌采用TP化疗方案。观察组在对照组化疗基础上联合应用胸腺五肽10 mg肌内注射，1次／d。疗程均为15d，共4个疗程。观察2组患者的临床效果、化疗前后呼气冷凝液及血清ET-1，血清ALB、CD4＋、CD8＋、CD4＋／CD8＋及NK的水平变化情况，采用EORTC QLQ-C30生存质量问卷调查表进行评分，并记录消化道不良反应发生情况。结果化疗后观察组总有效率明显高于对照组（63．8％vs．56．9％，χ2＝4．772， P ＝0．029），呼气冷凝液及血清ET-1水平低于对照组，血清ALB、CD4＋、CD8＋、CD4＋／CD8＋及NK水平、生存质量评分均显著高于对照组（ t ＝18．193、15．405、5．031、5．676、2．532、4．901、7．577， P ＝0．000、0．000、0．000、0．000、0．006、0．000、0．000）；观察组消化道反应发生率为15．5％，显著低于对照组的39．6％（χ2＝8．458， P ＝0．004）。结论胸腺五肽联合化疗治疗肺癌疗效确切，可降低呼气冷凝液及血清ET-1水平，抑制肿瘤转移程度，提高机体免疫功能，改善患者的生存质量。
展开▼
